Infectious diseases don't wait.
Neither do we

We protect children's futures from pregnancy through
adolescence with equitable science

Get to know us


Penta is an international independent scientific network dedicated to child health. Our work is the result of a passionate collaboration between healthcare professionals and researchers in 124 clinical sites and 26 cohorts across 27 countries around the world.

Through our studies and partnerships, we develop and deliver world-class research and training in paediatric infectious diseases to improve the lives of women and children, wherever they live.

Are you interested joining the Penta ID Network? Complete this form to apply.

Meet the 2026 Penta Brighter Future Award (BFA) winners!

This prestigious biennial award recognises visionary leaders dedicated to dismantling health inequities in maternal and child infectious diseases, specifically targeting HIV, tuberculosis (TB), vaccine access and the fortification of fragile health systems.

Penta Strategy 2025-2029: building on progress, driving strategic impact

Building on the results of our previous strategy, Penta’s 2025-2029 Strategic Plan focuses on accelerating scientific impact through high-quality research and strategic partnerships, especially in regions with the greatest need.

Penta advocates for equitable access to healthcare across all activities and strives to engage with affected and at-risk communities to maximise impact.

 

Current Penta studies around the World



Always expanding

Penta continues to grow, bringing together healthcare professionals, researchers and scientists worldwide to address a wide range of healthcare issues.
0

Members

0

Countries

0

Years of activity

0

Ongoing studies and projects

Previous

Latest News

Next

Penta at AIDS 2026 and the International Workshop on Pediatrics & HIV

09 Jul, 2026

We’re pleased to share that a large delegation of Penta experts is heading to Rio de Janeiro, Brazil at the end of the month, taking part in three major events…
Read More

Strengthening routine electronic health data to improve care for advanced HIV disease in children and adolescents in Uganda: UP ART-THRIVE study

02 Jul, 2026

Uganda continues to face a high HIV burden among children and adolescents, with an estimated 71,000 young people aged under 15 years living with HIV and 3,100 AIDS-related deaths in…
Read More

Penta joins international Phase 2 study of zelicapavir for the treatment of RSV in children

30 Jun, 2026

Fondazione Penta is pleased to be part of a new international clinical development programme led by Enanta Pharmaceuticals, a clinical-stage biotechnology company, to advance zelicapavir, a new oral antiviral in…
Read More

Antimicrobial resistance and children living with HIV: An overlooked threat

26 Jun, 2026

About the author My name is José Sumbana, a young African investigator and Postdoctoral Fellow with a background in Microbiology, Biotechnology, and Life Sciences.
Read More

Could an antiviral used for COVID-19 also help babies fight RSV? Early THAI-CARES RSV study results offer a first answer

25 Jun, 2026

Every winter, hospitals around the world fill with infants struggling to breathe because of respiratory syncytial virus (RSV). Estimates show that RSV infects nearly every child by the time they…
Read More

Keep up to date with the latest Penta news

Sign up to receive our monthly Penta Newsletter filled with the latest news on our studies, projects and people